Evotec AG today announced the publication of its fourth DDup edition. It focuses on epigenetic drug discovery and cancer which is the leading cause of death globally. DDup 4 highlights Evotec`s recently established alliance with Dana-Farber Cancer Institute and the Belfer Institute for Applied Cancer Science aiming to identify the next generation of epigenetic drug targets. This edition also provides insights into Evotec’s capabilities and expertise and its partners in the field of epigenetics, which include drug discovery and biomarker discovery experience, target validation workflows, in vivo models and genomic data to support identification of patient stratification biomarkers.